According to reports from Business Standard, Oxygenta Pharmaceutical reported a standalone net loss of ₹2.10 crore for the quarter ended June 2026, representing a significant improvement from the net loss of ₹6.11 crore recorded in the corresponding quarter of the previous financial year. The company's financial performance showed mixed results with substantial revenue growth but continued operational challenges.
As reported by Business Standard, the pharmaceutical company demonstrated strong revenue momentum with sales rising 144.55% to ₹37.00 crore in Q1 FY27 compared to ₹15.13 crore in the same quarter of the previous financial year. This substantial revenue growth indicates significant business expansion and market penetration during the quarter.
According to the financial data reported by Business Standard, the company's operating profit margin (OPM) improved to 1.51% in Q1 FY27 from -45.14% in the corresponding quarter of the previous year. Additionally, PBDT (Profit Before Depreciation and Tax) turned positive at ₹-1.88 crore compared to ₹-7.29 crore in Q1 FY26, showing operational efficiency improvements despite the net loss position.
As reported by Business Standard, the company's profit before tax (PBT) improved by 69% to ₹-2.50 crore in Q1 FY27 from ₹-8.14 crore in the previous year's corresponding quarter. The net loss reduction of 66% from ₹6.11 crore to ₹2.10 crore demonstrates the company's progress in managing operational costs and improving overall financial performance despite the continued loss position.
